文献速递淋巴瘤

ROSEWOOD:泽布替尼联合奥妥珠单抗对比奥妥珠单抗单药治疗复发或难治性滤泡性淋巴瘤的II期随机研究

ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
PubMed 文献 · J Clin Oncol · 2023-07-28

ROSEWOOD是一项II期随机研究,纳入既往接受过至少2线治疗(包括抗CD20抗体和烷化剂)的复发/难治性滤泡性淋巴瘤患者,按2:1随机接受泽布替尼联合奥妥珠单抗(ZO)或奥妥珠单抗单药治疗。主要终点独立中心评估的总缓解率ZO组为69%、O组为46%(P=0.001),中位无进展生存期ZO组28.0个月、O组10.4个月(HR 0.50,95%CI 0.33-0.75,P<0.001)。

要点

  • ZO组独立中心评估总缓解率69% vs O组46%(P=0.001),达到主要终点。
  • ZO组中位无进展生存期28.0个月 vs O组10.4个月(HR 0.50,95%CI 0.33-0.75)。
  • ZO组最常见不良事件为血小板减少、中性粒细胞减少、腹泻和疲乏。

核心结论

  • ZO对比O在复发/难治性滤泡性淋巴瘤患者中达到总缓解率优效的主要终点,显示出有意义的疗效和可控的安全性。
  • ZO相比O具有有利的获益-风险特征,是复发/难治性滤泡性淋巴瘤患者的潜在联合治疗方案。

研究设计与样本

  • ROSEWOOD是一项II期随机研究,评估泽布替尼联合奥妥珠单抗(ZO)对比奥妥珠单抗(O)在复发/难治性滤泡性淋巴瘤患者中的疗效和安全性。
  • 纳入既往接受过至少2线治疗(包括抗CD20抗体和烷化剂)的复发/难治性滤泡性淋巴瘤患者,按2:1随机分配接受ZO或O治疗。
  • 主要终点为独立中心评估的总缓解率,次要终点包括缓解持续时间、无进展生存期、总生存期和安全性。
  • 共217例患者随机分配(ZO组145例,O组72例),中位研究随访20.2个月。

主要发现

  • 独立中心评估的总缓解率ZO组为69%,O组为46%(P=0.001)。
  • 完全缓解率ZO组为39%,O组为19%。
  • 18个月缓解持续时间率ZO组为69%,O组为42%。
  • 中位无进展生存期ZO组为28.0个月,O组为10.4个月(风险比0.50,95%CI 0.33至0.75,P<0.001)。
  • ZO组最常见的不良事件为血小板减少、中性粒细胞减少、腹泻和疲乏;心房颤动和重大出血的发生率分别为3%和1%。

临床怎么用

  • 作者认为ZO相比O具有有利的获益-风险特征,是复发/难治性滤泡性淋巴瘤患者的潜在联合治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The combination of zanubrutinib plus obinutuzumab (ZO) was found to be well tolerated with an early signal of efficacy in a phase Ib study. ROSEWOOD is a phase II, randomized study that assessed the efficacy and safety of ZO versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL). METHODS: Patients with R/R FL who had received ≥2 lines of therapy, including an anti-CD20 antibody and an alkylating agent, were randomly assigned 2:1 to receive ZO or obinutuzumab (O). The primary end point was overall response rate (ORR) by independent central review (ICR). Secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival, and safety. RESULTS: A total of 217 patients were randomized (ZO, 145; O, 72). Median study follow-up was 20.2 months. The study met its primary end point: ORR by ICR was 69% (ZO) versus 46% (O; P = .001). Complete response rate was 39% (ZO) versus 19% (O); 18-month DOR rate was 69% (ZO) versus 42% (O). Median PFS was 28.0 months (ZO) versus 10.4 months (O; hazard ratio, 0.50 [95% CI, 0.33 to 0.75]; P < .001). The most common adverse events with ZO were thrombocytopenia, neutropenia, diarrhea, and fatigue; incidences of atrial fibrillation and major hemorrhage were 3% and 1%, respectively. CONCLUSION: The combination of ZO met its primary end point of a superior ORR versus O, and demonstrated meaningful activity and a manageable safety profile in patients with R/R FL. ZO had a favorable benefit-risk profile compared with O, and represents a potential combination therapy for patients with R/R FL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zinzani PL, Mayer J, Flowers CR, et al. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. J Clin Oncol. 2023. PMID: 37506346. doi:10.1200/JCO.23.00775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。